Tohyama K, Miyake T, Morinaga H, Futakuchi S, Izumi M, Yamanaka T, Egami H, Yamane T, Ga S, Fujishima K
Jpn J Antibiot. 1983 Jun;36(6):1439-42.
A clinical study was performed on concentration of cefotiam (CTM) in the gallbladder bile and the gallbladder tissue in benign diseases of the biliary tract. By an hour intravenous infusion the CTM concentration obtained 2 hours after the start of the infusion revealed that the level of the CTM in A bile was atmost same as that in B bile (3.1--46.0 micrograms/ml). The concentration in gallbladder tissue was 5.7--116 micrograms/ml. In addition, the CTM level was higher enough than the MIC of CTM covering more than 80% of the strains of E. coli and Klebsiella obtained from the focus. From these results, it is concluded that CTM is clinically effective and useful in the case of biliary disease.
对头孢替安(CTM)在胆道良性疾病患者胆囊胆汁及胆囊组织中的浓度进行了一项临床研究。通过静脉滴注1小时,在滴注开始2小时后测得的CTM浓度显示,A胆汁中CTM水平与B胆汁中CTM水平最高相同(3.1 - 46.0微克/毫升)。胆囊组织中的浓度为5.7 - 116微克/毫升。此外,CTM水平足够高于从病灶分离出的80%以上大肠杆菌和克雷伯菌菌株的CTM最低抑菌浓度(MIC)。从这些结果得出结论,CTM在胆道疾病的治疗中具有临床有效性和实用性。